

# Survey of Patients Who Were Prescribed Epinephrine Nasal Spray

Jake Rosenblum, DO,<sup>1</sup> Theodore Kelbel, MD,<sup>2</sup> Ali Doroudchi, MD,<sup>3</sup> Hary Katz, MD,<sup>4</sup> Thomas B. Casale, MD,<sup>5</sup> Margie Stelwagon,<sup>6</sup> Sarina Tanimoto, MD, PhD<sup>6</sup>  
<sup>1</sup>Allergy and Immunology, Mid Island Allergy Group, Plainview, NY, USA; <sup>2</sup>Pediatric Allergy and Immunology, Corewell Health Allergy and Immunology, Grand Rapids, MI, USA; <sup>3</sup>Allergy and Immunology, Modena Allergy & Asthma, La Jolla, CA, USA; <sup>4</sup>Pediatric Allergy and Immunology, Family Allergy & Asthma Consultants P.A., Jacksonville, FL, USA; <sup>5</sup>Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA; <sup>6</sup>ARS Pharmaceuticals Operations, Inc., San Diego, CA, USA.

## RATIONALE

- A 2 mg epinephrine nasal spray was approved by the FDA in August 2024 for the treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients (≥30 kg).
- While epinephrine is the only approved first-line treatment for anaphylaxis, treatment compliance is low, with only 50% of known reactions treated with epinephrine.
- The launch of an epinephrine nasal spray offers the first needle-free epinephrine delivery option and is expected to reduce barriers to rapid treatment.
- Patient satisfaction is a key metric for assessing impact on treatment compliance.

## METHODS

- Between February and May 2025, a 30-minute web-based survey was administered to adult allergy patients and adult caregivers of pediatric patients (n=400).
- The key screening criteria included the following:
  - **Diagnosed with severe allergy:** confirmatory testing or primary caregiver/decision-maker for a diagnosed child.
  - For caregiver sample, the **child must weigh at least 33 lbs.**
  - Patient must have **seen HCP for severe allergy in the past 12 months** and have **experienced at least 1 potentially life-threatening allergic reaction.**
  - All study participants, as patients or caregivers, **must be at least 18 years old.**
  - Respondent or immediate family must not work for the FDA or government, marketing or market research departments or companies, ad agencies, or for a pharma company or healthcare manufacturer.

## RESULTS

- Twenty-two patients or caregivers had filled a prescription for epinephrine nasal spray. Of those respondents, most were managed by an allergist (77%). The most common allergens were Insect bites/sting (59%), Peanuts (50%), Medication(s) (45%), Tree nuts (32%), and Milk (32%).
- Approximately 60% reported that they experienced a significant to moderate positive impact on their daily life and social life, while 40% reported it had no impact on either measure (see **Figure 1** and **Figure 2**).
- Among the 14 current users, 93% of respondents reported that they were likely to refill their epinephrine nasal spray prescription and 86% said they were satisfied with epinephrine nasal spray; no patients reported dissatisfaction (see **Figure 3** and **Figure 4**).

Figure 1: Impact on Daily Life




Figure 2: Impact on Social Life




Figure 3: Likelihood to Refill





Figure 4: Level of Satisfaction



## CONCLUSIONS

- Although access immediately after the initial launch was limited, resulting in a small number of respondents, this early data suggest that patients report a positive experience with epinephrine nasal spray and are likely to refill a prescription.

Take a picture or scan to view and download poster

